Abstract 【Objective】To explore the relationship between ovarian reserve function and thyroid function in women with perimenopausal syndrome. 【Methods】A total of 80 patients with perimenopausal syndrome treated in our hospital from January 2020 to January 2022 were selected. According to whether the patients had ovarian reserve function decline, the observation group (with ovarian function decline, n=50) and the control group (without ovarian function decline, n=30) were selected. Age at admission, body mass index (BMI), blood type, smoking history, age at menarche, age at first sex, age at first pregnancy, history of dysmenorrhea, menstrual period, menstrual cycle, number of abortions, pregnancy times, pelvic inflammatory disease and sleep quality were collected. The levels of thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) were detected in both groups at admission. The differences of basic data and laboratory indicators between the two groups were compared. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of TSH, FT3 and FT4 levels for ovarian reserve function decline in women with perimenopausal syndrome. Unconditional logistic regression was used to analyze the risk factors for ovarian reserve decline in women with perimenopausal syndrome. 【Results】The levels of TSH, FT3 and FT4 in the observation group were significantly higher than those in the control group, and the differences were statistically significant (P<0.05). The areas under the ROC curve of TSH, FT3 and FT4 levels in predicting ovarian reserve decline in women with perimenopausal syndrome were 0.879, 0.987 and 0.924, respectively. Multivariate Logistic regression analysis confirmed that TSH≥2.516 mIU/L, FT3≥4.669 pmol/L, FT4≥15.577 pmol/L were risk factors for ovarian reserve decline in women with perimenopausal syndrome (all P<0.05). 【Conclusion】TSH, FT3 and FT4 can be used as blood indicators to predict the decline of ovarian reserve function in female patients with menopausal syndrome. Thus, these parameters provide reference for the prevention and treatment of such patients, which is worthy of clinicians' attention.
SI Mei-li,SHI Fan. Relationship between Ovarian Reserve Function and Thyroid Function in Women with Perimenopausal Syndrome[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(9): 1392-1394.
[1] CAULEY J A,KRISTINE R,LIAN Y,et al.Serum sex hormones and the risk of fracture across the menopausal transition:study of women's health across the nation[J].J Clin Endocrinol Metabol,2019,104(6):2412-2418. [2] ZHOU Q M,ZHANG X H.Prevalence and related factors of hot flashes about women during menopausal transition or postmenopause in gansu province[J].J Internat Obstet Gynecol,2019,46(3):355-360. [3] 刘蔚,李萍,李小娟.不同剂量结合雌激素联合天然孕激素对围绝经期综合征患者性激素水平及骨密度的影响[J].医学临床研究,2021,38(12):1871-1873. [4] ZHONG Z,DONG H,WANG H,et al.Electroacupuncture for the treatment of perimenopausal syndrome:a systematic review and meta-analysis of randomized controlled trials [J].Acupunct Med,2022,40(2):111-122. [5] 谢聪聪,王雪莹,姚冠峰,等.甲状腺激素在卵泡发生中作用的研究进展[J].基础医学与临床,2019,39(3):428-433. [6] 曹丹凤,熊慧峰.围绝经期综合征患者甲状腺激素性腺激素及糖脂代谢指标水平与骨密度的相关性[J].中国妇幼保健,2021,36(19):4595-4598. [7] 于传鑫.实用妇科内分泌学[M].上海:复旦大学出版社,2004:157-158. [8] 曹泽义.中华妇产科学[M].北京:人民卫生出版社,2014:2535. [9] 曲华,高铸烨,史大卓.基于肝藏血主疏泄脏象理论辨治围绝经期综合征[J].中华中医药杂志,2019,34(11):5460-5462. [10] HHCA B,LIT B,CYL B,et al.Using a short questionnaire of the perimenopausal fatigue scale to evaluate perimenopausal women prone to fatigue syndrome[J].Taiwan J Obstet Gynecol,2021,60(4):734-738. [11] 刘群香,李瑞青,叶海丽.小剂量雌孕激素替代治疗对围绝经期综合征患者性激素水平的影响[J].中国妇幼保健,2020,35(11):2047-2050. [12] 张航清,马麟娟.谷维素联合芬吗通治疗围绝经期综合征的疗效及对患者血清神经递质和激素水平的影响[J].中国妇幼保健,2021,36(13):3121-3123. [13] 丁桂英,余晓.小剂量雌孕激素替代疗法治疗围绝经期综合征的疗效及激素变化探析[J].中国性科学,2019,28(4):104-107. [14] 刘颖群,周莹,张小翠,等.固阴煎加减对育龄期卵巢低反应肾阴虚型患者卵巢储备功能的影响[J].中国实验方剂学杂志,2019,25(10):87-92. [15] 赵罂,梁东.育龄期妇女卵巢储备功能下降与甲状腺功能相关性的临床研究[J].解放军预防医学杂志,2019,37(3):148-149. [16] 杨名慧,祝小波,王文华,等.甲状腺自身抗体阳性患者甲状腺功能,卵巢功能和炎症因子的检测及临床价值分析[J].中国卫生检验杂志,2020,30(17):2115-2119. [17] 魏景蕊,袁巾惠,白晶莹,等.评估卵巢储备功能的常用指标对预测卵巢反应性的价值比较[J].生殖医学杂志,2020,29(1):27-32. [18] 曹丽.甲状腺功能异常患者FT3、FT4、TSH与T3、T4联合检测的临床价值[J].临床检验杂志,2019,8(2):49-50. [19] 冯畅,施克新,杨梅,等.甲状腺激素水平与更年期综合征女性情绪障碍程度,性激素水平及免疫功能的相关性分析[J].临床和实验医学杂志,2020,19(24):2654-2657. [20] 何婷玉,王惠玲,荣蓓,等.围绝经期抑郁症患者的血清甲状腺激素水平研究[J].神经损伤与功能重建,2020,15(6):331-334.
2022, Vol. 39 
